Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $224.77 -1.03%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
